Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics and Medarex Establish Alliance to Develop Human Antibody Therapeutics
Medarex to invest $2 million in Seattle Genetics Bothell, WA and Princeton, NJ: February 7, 2001— Seattle Genetics, Inc. and Medarex, Inc. (Nasdaq: MEDX) today announced the formation of a strategic alliance through which the two companies expect to utilize Medarex's UltiMAb™ Human Antibody
View HTML
Toggle Summary Seattle Genetics Initiates Phase II Clinical Trial in Prostate Cancer
Bothell, WA – November 30, 2000 – Seattle Genetics, Inc. announced the initiation of a phase II clinical trial with one of its lead drug candidates, SGN-15. The trial will evaluate the monoclonal antibody-drug conjugate SGN-15 in combination with the chemotherapeutic drug Taxotere® for patients
View HTML
Toggle Summary Seattle Genetics Files For Initial Public Offering of Common Stock
Bothell, WA - November 20, 2000 - Seattle Genetics, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for an initial public offering of its common stock. All of the shares to be registered will be offered by Seattle Genetics. J.P.
View HTML
Toggle Summary Seattle Genetics Signs Development and Manufacturing Agreement with ICOS
Bothell, WA - November 9, 2000 – Seattle Genetics, Inc. announced today that it has signed a development and manufacturing agreement with ICOS Corporation (Nasdaq:ICOS). Under the terms of the agreement, ICOS will conduct development, scale-up and manufacturing in its cell culture manufacturing
View HTML
Toggle Summary Seattle Genetics Initiates Phase II Clinical Trials With SGN-15
Two Trials Commencing for Patients With Breast or Colorectal Cancers Bothell, WA – October 31, 2000 – Seattle Genetics, Inc. announced the initiation of phase II clinical testing with one of its lead monoclonal antibody drug conjugates, SGN-15. “We are very excited to progress into phase II with
View HTML
Toggle Summary Seattle Genetics Initiates Phase I Clinical Trial of SGN-10 in Combination with Taxotere for Patients with Carcinoma
Bothell, WA – September 19, 2000 – Seattle Genetics, Inc. announced the initiation of a second phase I clinical trial with its single-chain immunotoxin, SGN-10. This study will evaluate SGN-10 in combination with Taxotere® for patients with advanced carcinoma.
View HTML
Toggle Summary Renowned Cancer Researcher Joins Seattle Genetics Board; CFO Appointed
Bothell, WA – August 1424, 2000 – Seattle Genetics today announced that Dr. Marc Lippman, the Director of the Lombardi Cancer Research Center at Georgetown University Medical School, has joined Seattle Genetics'its Board of Directors. Dr. Lippman is Professor and Chairman of the Department of
View HTML
Toggle Summary Seattle Genetics, Inc. Completes $30 Million Financing to Expand Monoclonal Antibody-Based Therapy Programs
Bothell, Washington, March 14, 2000-Seattle Genetics, Inc., has raised $30 million in private financing to fight cancer. The Series B financing was led by Bank of America Ventures. Additional investors include Cascade Investment, Vulcan Ventures, Olympic Venture Partners, Sofinnova Ventures, and
View HTML